Madrigal appoints Bill Sibold as President & CEO, effective Sept 8, 2023

MADRIGAL PHARMACEUTICALS, INC.

Bill Sibold appointed President & CEO effective Sept 8, 2023; also joins Board as Class II director.
Sibold compensation: $875k base salary, 75% target bonus, $520k sign-on cash, 50k time-based RSUs, 50k performance PSUs.
Former CEO Paul Friedman steps down but remains on Board; receives 12 months base salary plus 100% of target bonus.
Sibold previously EVP Specialty Care at Sanofi; prior roles at Biogen, Avanir. Yale BA, Harvard MBA.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bill Sibold

President and Chief Executive Officer

MDGL · MADRIGAL PHARMACEUTICALS, INC.

Effective: 2023-09-08
Filed: September 13, 2023, 7:59 PM ET

The Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”) appointed Bill Sibold as the President and Chief Executive Officer of the Company, increased the Board size to nine and appointed Bill Sibold as a member of the Board, in each case effective as of 5:01 p.m. ET on September 8, 2023 (the “Start Date”).

Departed

Paul Friedman

Chief Executive Officer

MDGL · MADRIGAL PHARMACEUTICALS, INC.

Effective: 2023-09-08
Successor: Bill Sibold
Filed: September 13, 2023, 7:59 PM ET

As of the Start Date, Dr. Friedman stepped down as Chief Executive Officer but will continue to serve as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bill Sibold was appointed as President and Chief Executive Officer at MADRIGAL PHARMACEUTICALS, INC..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

The Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”) appointed Bill Sibold as the President and Chief Executive Officer of the Company, increased the Board size to nine and appointed Bill Sibold as a member of the Board, in each case effective as of 5:01 p.m. ET on September 8, 2023 (the “Start Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul Friedman departed as Chief Executive Officer at MADRIGAL PHARMACEUTICALS, INC..

Action: stepped down
Role: Chief Executive Officer

Exact text from the filing

As of the Start Date, Dr. Friedman stepped down as Chief Executive Officer but will continue to serve as a director of the Company.

View on SEC.gov

MADRIGAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-234395

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.